<?xml version="1.0" encoding="UTF-8"?>
<xbrli:xbrl xmlns:in-capmkt="https://www.sebi.gov.in/xbrl/2023-05-31/in-capmkt" xmlns:in-capmkt-ent="https://www.sebi.gov.in/xbrl/Prior_Intimation_Of_Board_Meeting/2023-05-31/in-capmkt/in-capmkt-ent" xmlns:in-capmkt-roles="https://www.sebi.gov.in/xbrl/Prior_Intimation_Of_Board_Meeting/2023-05-31/in-capmkt-roles" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:in-capmkt-type="https://www.sebi.gov.in/xbrl/2023-05-31/in-capmkt-types" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink">
<link:schemaRef xlink:type="simple" xlink:href="in-capmkt-ent-2023-05-31.xsd"/>

<xbrli:unit id="INR"><xbrli:measure>iso4217:INR</xbrli:measure></xbrli:unit><xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="INRPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:INR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<in-capmkt:NSESymbol contextRef="OneI">VIVIMEDLAB</in-capmkt:NSESymbol>
<in-capmkt:NameOfTheCompany contextRef="OneI">VIVIMED LABS LIMITED</in-capmkt:NameOfTheCompany>
<in-capmkt:ISIN contextRef="OneI">INE526G01021</in-capmkt:ISIN>
<in-capmkt:TypeOfMeeting contextRef="OneI">Board Meeting</in-capmkt:TypeOfMeeting>
<in-capmkt:TypeOfIntimation contextRef="OneD">New</in-capmkt:TypeOfIntimation>
<in-capmkt:DateOfProposedMeeting contextRef="OneD">2025-08-13</in-capmkt:DateOfProposedMeeting>
<in-capmkt:WhetherTradingWindowIsClosed contextRef="OneD">Yes</in-capmkt:WhetherTradingWindowIsClosed>
<in-capmkt:DateOfStartOfTradingWindowClosure contextRef="OneI">2025-07-01</in-capmkt:DateOfStartOfTradingWindowClosure>
<in-capmkt:DetailsOfDateOfEndOfTradingWindowClosure contextRef="OneI">2025-08-16</in-capmkt:DetailsOfDateOfEndOfTradingWindowClosure>
<in-capmkt:Agenda1 contextRef="OneD">Financial results</in-capmkt:Agenda1>
<in-capmkt:Agenda2 contextRef="OneD">Fund raising</in-capmkt:Agenda2>
<in-capmkt:Agenda3 contextRef="OneD">Other business</in-capmkt:Agenda3>
<in-capmkt:WhetherResultsAreAuditedOrUnaudited contextRef="OneD">Unaudited</in-capmkt:WhetherResultsAreAuditedOrUnaudited>
<in-capmkt:NatureOfReportStandaloneConsolidated contextRef="OneD">Standalone And Consolidated</in-capmkt:NatureOfReportStandaloneConsolidated>
<in-capmkt:ReportingPeriodType contextRef="OneD">Quarterly</in-capmkt:ReportingPeriodType>
<in-capmkt:MonthOfPeriodEnded contextRef="OneD">June</in-capmkt:MonthOfPeriodEnded>
<in-capmkt:YearOfPeriodEnded contextRef="OneI" unitRef="INR" decimals="0">2025</in-capmkt:YearOfPeriodEnded>
<in-capmkt:ModeOfRaisingFunds contextRef="OneD">Any other method</in-capmkt:ModeOfRaisingFunds>
<in-capmkt:RemarksWebsiteDissemination contextRef="OneI">-Board Report    - AGM for FY2025 &amp; related matters.  -Proposal for raising of funds by issuance of equity shares / convertible bonds / debentures / warrants / preference shares / any other equity linked securities (“Securities”) through permissible modes including by way of a private placement, including through a preferential issue or qualified institutions placement of Securities or any other method or mode as may be permitted under applicable laws, including the Companies Act, 2013 read with the rules notified thereunder and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, and to approve ancillary actions for the above mentioned fund raising subject to such regulatory/statutory approvals as may be required including approval of shareholders in this regard</in-capmkt:RemarksWebsiteDissemination>
</xbrli:xbrl>